82964-04-3 | Tolrestat

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$42.00	$29.00
5mg	98%	in stock	$150.00	$105.00
10mg	98%	in stock	$276.00	$193.00
25mg	98%	in stock	$587.00	$411.00

Description

• Catalog Number: AH51130
• Chemical Name: Tolrestat
• CAS Number: 82964-04-3
• Molecular Formula: C16H14F3NO3S
• Molecular Weight: 357.3475
• MDL Number: MFCD00864170
• SMILES: COc1ccc2c(c1C(F)(F)F)cccc2C(=S)N(CC(=O)O)C

Computed Properties

• Complexity: 486
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 24
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.7

Upstream Synthesis Route

N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine is a versatile compound widely utilized in chemical synthesis processes. This compound serves as a key building block in the creation of pharmaceuticals, agrochemicals, and materials due to its unique structural characteristics and reactivity.In chemical synthesis, N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine is employed as a potent nucleophile, allowing for the formation of strong carbon-carbon and carbon-heteroatom bonds. Its thioxomethyl group enhances its nucleophilicity, making it a valuable reagent in various transformations such as alkylations, acylations, and condensations.Furthermore, the presence of the trifluoromethyl moiety in the structure of this compound imparts beneficial properties to the synthesized products, such as increased lipophilicity, metabolic stability, and bioactivity. This makes N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine a valuable tool in the design and synthesis of new chemical entities with improved pharmacokinetic profiles and biological activities.Overall, the strategic incorporation of N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine in chemical synthesis endeavors enables researchers to access diverse molecular scaffolds and functional groups, driving innovation in drug discovery, materials science, and other chemistry-related fields.

Literature

• X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.

  Chemico-biological interactions 20130225

• Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation.

  Experimental eye research 20120801

• The good, the bad and the twisted: a survey of ligand geometry in protein crystal structures.

  Journal of computer-aided molecular design 20120201

• Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.

  Frontiers in pharmacology 20120101

• The isolation and characterization of β-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis.

  PloS one 20120101

• Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.

  Frontiers in pharmacology 20120101

• Implication of crystal water molecules in inhibitor binding at ALR2 active site.

  Computational and mathematical methods in medicine 20120101

• Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

  Journal of lipid research 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Structure of aldose reductase from Giardia lamblia.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20110901

• Efficacy of structurally diverse aldose reductase inhibitors on experimental periodontitis in rats.

  Journal of periodontology 20110601

• Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.

  Journal of natural products 20110527

• Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice.

  Diabetologia 20110501

• Systematic exploitation of multiple receptor conformations for virtual ligand screening.

  PloS one 20110101

• Increased recruitment but impaired function of leukocytes during inflammation in mouse models of type 1 and type 2 diabetes.

  PloS one 20110101

• Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma.

  Respiratory research 20110101

• Osmolarity and glucose differentially regulate aldose reductase activity in cultured mouse podocytes.

  Experimental diabetes research 20110101

• Diabetic neuropathy: a cross-sectional study of the relationships among tests of neurophysiology.

  Diabetes care 20101201

• Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study.

  Diabetes care 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.

  Yonsei medical journal 20100501

• Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.

  Bioorganic & medicinal chemistry 20100401

• Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.

  European journal of medicinal chemistry 20100301

• Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.

  Biological & pharmaceutical bulletin 20100101

• Rat aldose reductase-like protein (AKR1B14) efficiently reduces the lipid peroxidation product 4-oxo-2-nonenal.

  Biological & pharmaceutical bulletin 20100101

• Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years.

  Clinical ophthalmology (Auckland, N.Z.) 20100101

• Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue.

  Diabetes 20091101

• Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice.

  Circulation research 20091009

• Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.

  Journal of molecular graphics & modelling 20090901

• Elevated triglycerides correlate with progression of diabetic neuropathy.

  Diabetes 20090701

• Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.

  Archives of biochemistry and biophysics 20090701

• Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress.

  Chemico-biological interactions 20090316

• Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7.

  Journal of biochemistry 20090201

• Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.

  Bioorganic & medicinal chemistry 20090201

• The cycle of genome-directed medicine.

  Genome medicine 20090101

• Advances in pharmacological strategies for the prevention of cataract development.

  Indian journal of ophthalmology 20090101

• Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.

  Diabetic medicine : a journal of the British Diabetic Association 20080701

• Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.

  Journal of molecular biology 20080620

• Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.

  Journal of medicinal chemistry 20080612

• Role of nitric oxide in regulating aldose reductase activation in the ischemic heart.

  The Journal of biological chemistry 20080404

• Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes.

  Experimental diabetes research 20080101

• Diabetic retinopathy: an update.

  Indian journal of ophthalmology 20080101

• C-Peptide effects on renal physiology and diabetes.

  Experimental diabetes research 20080101

• Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.

  Proceedings of the National Academy of Sciences of the United States of America 20071226

• Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.

  Vascular health and risk management 20071201

• Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.

  Journal of molecular biology 20071109

• Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.

  The Cochrane database of systematic reviews 20071017

• Aldose reductase-regulated tumor necrosis factor-alpha production is essential for high glucose-induced vascular smooth muscle cell growth.

  Endocrinology 20070901

• Evidence for a novel binding site conformer of aldose reductase in ligand-bound state.

  Journal of molecular biology 20070525

• PocketPicker: analysis of ligand binding-sites with shape descriptors.

  Chemistry Central journal 20070101

• Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells.

  Investigative ophthalmology & visual science 20061201

• Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages.

  Cytokine 20061101

• Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.

  Journal of molecular biology 20061013

• Phenolic marine natural products as aldose reductase inhibitors.

  Journal of natural products 20061001

• Assessment of basic indirect pharmacodynamic response models with physiological limits.

  Journal of pharmacokinetics and pharmacodynamics 20060401

• Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells.

  Diabetes 20060401

• High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.

  Journal of molecular biology 20060210

• Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.

  Journal of medicinal chemistry 20050505

• Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.

  Endocrine reviews 20050501

• Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells.

  Diabetes 20050301

• Spirohydantoin derivatives of thiopyrano[2,3-b]pyridin-4(4H)-one as potent in vitro and in vivo aldose reductase inhibitors.

  Bioorganic & medicinal chemistry 20050117

• Aldose reductase-catalyzed reduction of aldehyde phospholipids.

  The Journal of biological chemistry 20041217

• Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase.

  Diabetes 20041101

• Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801

• Aldose reductase regulates TNF-alpha-induced cell signaling and apoptosis in vascular endothelial cells.

  FEBS letters 20040716

• Rational design of an indolebutanoic acid derivative as a novel aldose reductase inhibitor based on docking and 3D QSAR studies of phenethylamine derivatives.

  Journal of medicinal chemistry 20031218

• Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.

  Journal of medicinal chemistry 20031120

• Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism.

  The Biochemical journal 20030801

• Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.

  Journal of medicinal chemistry 20030410

• Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030201

• Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay.

  Chemico-biological interactions 20030201

• Aldose reductase mediates the mitogenic signals of cytokines.

  Chemico-biological interactions 20030201

• Role of aldose reductase in TNF-alpha-induced apoptosis of vascular endothelial cells.

  Chemico-biological interactions 20030201

• Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.

  Journal of medicinal chemistry 20030130

• Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes.

  Diabetes 20021001

• Aldose reductase is an obligatory mediator of the late phase of ischemic preconditioning.

  Circulation research 20020809

• Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

  Bioorganic & medicinal chemistry 20020401

• Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20020101

• Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.

  Diabetes, obesity & metabolism 20020101

• [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.

  Journal of medicinal chemistry 20011206

• Aldose reductase inhibitors.

  Journal of enzyme inhibition 20011201

• Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells.

  Atherosclerosis 20011001

• Involvement of aldose reductase in the metabolism of atherogenic aldehydes.

  Chemico-biological interactions 20010130

• Regulation of vascular smooth muscle cell growth by aldose reductase.

  Chemico-biological interactions 20010130

• Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.

  Journal of medicinal chemistry 20000323

• Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.

  Journal of medicinal chemistry 19850701

• N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.

  Journal of medicinal chemistry 19840301